U.S. Securities and Exchange Commission
Washington, D.C. 20549 (202) 942-0020

News Release

FOR IMMEDIATE RELEASE 96-133

COMMISSION POSTS OMNIGENE NOTICE ON AMERICA ONLINE

Washington, D.C., November 20, 1996 -- At 9:30 this morning (EST), in response to serious questions raised about OmniGene Diagnostics, Inc., of West Palm Beach, Florida, the Securities and Exchange Commission suspended trading in the company's stock.

The SEC also took the additional step of posting information about the suspension, including its Order Suspending Trading, on an America OnLine message board that discussed OmniGene stock.

"While the Commission has thus far used the Internet through its Web site <www.sec.gov> to solicit information about possible fraudulent activities, we will now be using the Internet to alert investors to potential problems with specific securities when circumstances warrant. This is the first time we've done so, but it will not be the last," said William McLucas, Director of the Division of Enforcement.

A copy of the posting made by the SEC is attached.

# # #

PLEASE NOTE THAT THIS POSTING IS BEING MADE BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.

SECURITIES EXCHANGE ACT OF 1934
RELEASE NO. 34-37966

The Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the "Exchange Act"), of over-the-counter trading of the securities of OmniGene Diagnostics, Inc. ("ODI"), of West Palm Beach, Florida at 9:30 a.m. EST, on November 20, 1996, and terminating at 11:59 p.m. on December 4, 1996.

The Commission temporarily suspended trading in the securities of ODI because of questions that have been raised about the accuracy and adequacy of publicly disseminated information concerning, among other things, ODI's alleged ownership and other rights as to certain patents and trademarks, ODI's sales, past and projected, ODI's operations and facilities, and the number of freely traded shares of ODI common stock.

The Commission cautions broker-dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company.

Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker of dealer has any questions as to whether or not he has complied with the rule, he should not enter any quotation but immediately contact the staff of the Securities and Exchange Commission in Washington, D.C. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, he should refrain from entering quotations relating to ODI's securities until such time as he has familiarized himself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action.

If any broker-dealer or other person has any information which may relate to this matter, please contact Terence Tennant at the Miami, Florida office of the Securities and Exchange Commission should be telephoned at (305) 982-6346.

Here is an unofficial copy of the Commission order suspending trading.

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

OMNIGENE DIAGNOSTICS, INC.

File No. 500-1

ORDER OF SUSPENSION OF TRADING

It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of OmniGene Diagnostics, Inc. ("ODI"), because of questions regarding the accuracy of assertions by ODI, and by others, in documents sent to, and statements made to, market-makers of the stock of ODI, other broker-dealers, and to investors concerning, among other things, ODI's alleged ownership and other rights as to certain patents and trademarks, ODI's sales, past and projected, ODI's operations and facilities, and the number of freely traded shares of ODI common stock.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.

Therefore, it is ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the above-listed company is suspended for the period from 9:30 a.m. EST, November 20, 1996 through 11:59 p.m. EST, on December 4, 1996.

By the Commission.

Jonathan G. Katz
Secretary